Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age

Trial Profile

Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Protein Sciences Corporation
  • Most Recent Events

    • 18 Nov 2020 According to a Sanofi media release, based on two phase studies (NCT02285998 and NCT02290509) the European Commission has granted a marketing authorization for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older.
    • 09 Sep 2017 Results published in the Journal of Infectious Diseases.
    • 26 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top